RU2494747C1 - Method for drug-free hyperlipidaemia reduction - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to experimental medicine and concerns drug-free blood hyperglycemia relief in experimental animals. For this purpose, beetroot pectin in the amount of 100 mcg/kg a day is introduced into the diet of inbred white rats simultaneously with the atherogenic diet.

EFFECT: method provides decreasing the hyperlipidaemia level ensured by reducing total cholesterol, triglycerides, very low density lipoprotein (VLDLP) and low-density lipoproteins (LDLP) in animal's blood.

1 tbl, 1 ex

Description

The invention relates to medicine, as well as nutrition, and can be used to prevent metabolic disorders, especially lipid and cholesterol metabolism.

Currently, there is a rapid increase in metabolic disorders, especially fat metabolism disorders, the main reason for which is increased nutrition with simultaneous limited mobility. The content of certain lipids in the blood gradually increases (total cholesterol, triacylglycerides (TG), very low density lipoproteins (VLDL) and low density lipoproteins (LDL), which increase the risk of atherosclerotic heart and peripheral vascular diseases. The natural mechanism for regulating hyperlipidemia in case of a diet rich in fats and this leads to a continuous increase in blood plasma cholesterol. Hyperlipidemia is at least partially responsible for the formation of arteriosclerotic pain. shek in the vessels.

Known methods for reducing hyperlipidemia by using fungi of the class Basidiomycetes of various species from the genus Pleurotus, Nina Gunde-Cimerman. Medicinal Value of the Genus Pleurotus (Fr.) P. Karst. (Agaricales S.I., Basidiomycetes) // International Journal of Medicinal Mushrooms: 1999. Vol. 1 / pp. 69-71; US No. 6372964, 435/171, 424 / 195.15, 435 / 254.1, 435 / 256.8, publ. 2002.04.16).

Known methods for the non-drug reduction of hyperlipidemia using the products of the deep cultivation of the fungus Panus conchatus in the form of biomass or extract from it in the diet (RU 2348422, IPC A61K 36/07, A61P 3/06, publ. 10.03.2009), the use of deep cultivation products one of the xylophytic fungi Trametes hirsute TI-14, Trametes ochracea TI-15, Panus conchatus TI-16, Cerrena unicolor TI-9, Ganoderma licidum TI-7, Flammulma velutipes TI-3 (RU 2358782, IPC A61P 3/06, publ June 20, 2009).

The closest technical solution to the claimed is a drug for the prevention and treatment of lipoid and cholesterol metabolism, which is galacturonic acid or its derivatives selected from the group comprising α-D-galacturonic acid and its polymers, methyl ester of galacturonic acid and its polymers, tertiary or quaternary amine-containing esters and acetals of galacturonic acid or their polymers, as well as fermented pectin (RU 2108788, IPC A61K 31/725, A61K 31/73, opu Bl. 04/20/1998).

A disadvantage of the known solution is the use of a complex synthesized polysaccharide, which significantly increases the final cost of the drug and does not exclude the presence of by-products of biosynthesis, which can lead to a decrease in the beneficial effect.

The technical result consists in reducing the level of total cholesterol and triacylglycerides, very low density lipoproteins (VLDL) and low density lipoproteins (LDL) in the blood of animals. An increase in high density lipoproteins and a decrease in the atherogenicity index are also observed. In addition, the cost of the proposed method is reduced.

The essence of the invention lies in the fact that beet pectin in the amount of 100 μg / kg per day for 21 days is introduced into the diet of animals simultaneously with an atherogenic diet.

Beet pectin is a galacturonic acid heteropolymer containing neutral carbohydrates whose general formula is:

Beet pectin was obtained according to the technology of isolation from plant materials (in this case beet pulp) pectin used for the production of preventive and therapeutic products (RU 2322456, IPC C08B 37/06, published on 04/20/2008).

The method is as follows.

The animals are kept on an atherogenic diet (wheat porridge, butter - 5% and lard - 25% of the weight of the food, as well as an emulsion of cholesterol in vegetable oil (through a probe) at a rate of 0.4 g / kg body weight, vitamin D - 200 thousand IU / day). In addition, beet pectin in the amount of 100 μg / kg per day in the form of a powder for 21 days is introduced into the diet of animals on an atherogenic diet.

A significant decrease in the level of hyperlipidemia was confirmed in the experiment. The experiment was conducted on white outbred male rats weighing 140-160 g, obtained from the vivarium of the Mordovian State University named after N.P. Ogareva. " The model of hyperlipidemia of white outbred male rats was selected based on the experience of the Institute of Experimental Medicine of the Russian Academy of Medical Sciences (St. Petersburg) and foreign works (Staprans I., Rapp JH, Pan XM. Et al., Oxidized lipids in the diet accelerate the development of fatty streaks in cholesterol-fed rabbits, Arterioscl. Thromb. Vase. Biol., 1996, v. 16, No. 4, 533-538).

EXAMPLE 1. The experiment. In animals (white outbred male rats) experimentally induced hyperlipidemia was created by using a special atherogenic diet as their daily diet for three weeks (21 days). Animals were divided into several groups. The intact group (10 animals) received a standard diet of vivarium and tap water. The control group (10 animals) received an atherogenic diet (wheat porridge, butter - 5% and lard - 25% of the weight of the food, as well as an emulsion of cholesterol in vegetable oil (through a probe) at the rate of 0.4 g / kg body weight, vitamin D - 200 thousand IU / day) and water. The animals of the experimental group (10 animals), along with an atherogenic diet, received a supplement of 100 μg / kg per day of beet pectin for 3 weeks. All animals had free access to food and water. In all groups, total cholesterol, cholesterol of high density lipoproteins (HDL), low density lipoproteins (LDL) and very low density lipoproteins (VLDL), triglycerides in the blood were determined. After 21 days, the animals were withdrawn from the experiment under ether anesthesia. This work was carried out in compliance with all the rules and international recommendations of the "European Convention for the Protection of Vertebrate Animals Used in Experimental Works". Blood was drawn, which was stabilized with heparin in a ratio of 1000: 6. The content of total cholesterol (total cholesterol) and HDL cholesterol was determined using the Olveks Diagnostic kit (St. Petersburg, Russia) using a method based on a combination of an enzymatic reaction with an oxidation reaction. Hydrogen peroxide formed as a result of these reactions interacts with 4-aminophenazone and phenol under the action of peroxidase to form a colored product - quinonymine. The determination of triglycerides was performed in blood serum using the enzymatic colorimetric method using a set of reagents for determining triglycerides (TG) in human serum or whole blood VITAL DIAGNOSTICS (St. Petersburg, Russia). Using the Friedwald formula, the most important diagnostic criteria for the tendency to develop dyslipidemia and atherosclerosis, such as the concentration of LDL cholesterol and VLDL cholesterol, were calculated.

XL VLDLP = XC TG / 2.2 [mmol / L],

HDL cholesterol = total cholesterol VLDL-HDL cholesterol [mmol / l].

The content of total cholesterol, triglycerides, HDL cholesterol, LDL and VLDL in the blood serum of animals of the intact group, the control group and the experimental groups are presented in table 1. Note: the atherogenic coefficient (CA) is expressed through the ratio of the difference between the total cholesterol content (total cholesterol) and HDL cholesterol to HDL content and allows us to judge the degree of threat of the development of the atherosclerotic process in the body (Klimov A.N. High density lipoprotein antiatherogenic function. C .34-54; in the book: Atherosclerosis. Problems of pathogenesis and therapy. Publishing house "Medical literature", St. Petersburg., 2006. P.246).

A decrease in the level of induced hyperlipidemia in rats is observed under the influence of the inclusion of beet pectin in the diet (Table 1). So in animals of the control group (atherogenic diet) compared with the intact group:

- the concentration of total cholesterol (total cholesterol) in the blood serum increased by 92%;

- the content of triglycerides (TG) in the blood serum increased by 296%;

- the concentration of HDL in serum was 0.68 ± 0.04 mmol / L (in the intact group 1.15 ± 0.07 mmol / L);

- the atherogenic coefficient (KA) increased to 4.91;

- the concentration of LDL in serum increased by 230%;

- the concentration of VLDL in serum increased by 295%.

In animals of the experimental group (hyperlipidemic food plus 100 μg / kg of beet pectin in comparison with the control group:

- the concentration of total cholesterol in serum decreased by 46%;

- the content of triglycerides in serum decreased by 71%;

- the concentration of HDL in serum increased and amounted to 1.03 ± 0.02 mmol / L (in the control group 0.68 ± 0.04 mmol / L);

- the coefficient of atherogenicity (KA) was 1.11;

- the concentration of LDL in serum decreased by 62%;

- the concentration of VLDL in serum decreased by 71%;

Thus, the introduction of beet pectin into the atherogenic diet of animals not only reduces the level of total cholesterol, triglycerides, VLDL and LDL in the blood serum, but also maintains a high content of “good cholesterol” (HDL), which leads to a significant decrease in the level of hyperlipidemia (as evidenced by low coefficient of atherogenicity) and, therefore, to reduce the risk of developing an atherosclerotic process in the animal body.

Using the proposed method allows you to:

- use beet pectin to lower cholesterol, triglycerides, LDL and VLDL in the blood of animals, increase the level of HDL in the blood, which generally leads to a significant decrease in the level of hyperlipidemia;

- expand the implementation of the method by introducing into the diet of beet pectin for therapeutic and prophylactic purposes.

In addition, the use of beet pulp for the production of pectin creates the prerequisites for the development of waste-free production on the basis of the agricultural industry of the Republic of Mordovia.

Table 1 A decrease in the level of induced hyperlipidemia in rats under the influence of the inclusion of beet pectin in the diet Intact group (standard food) Control group (atherogenic diet) Experimental group (atherogenic diet + beet pectin) Total cholesterol (mmol / l) 2.09 ± 0.03 4.02 ± 0.02 2.17 ± 0.03 Compared to the stroke group - + 92% + 4% Compared to the control group - - -46% Triglycerides (mmol / L) 0.81 ± 0.01 3.21 ± 0.01 0.92 ± 0.05 Compared to the intact group - + 296% + 14% Compared to the control group - - -71% HDL (mmol / L) 1.15 ± 0.07 0.68 ± 0.04 1.03 ± 0.02 Compared to the intact group -59% -10% Compared to control group + 51% LDL (mmol / L) 0.57 ± 0.03 1.88 ± 0.04 0.72 ± 0.05 Compared to the intact group + 230% + 26% Compared to the control troupe -62% VLDLP (mol / L) 0.37 ± 0.03 1.46 ± 0.04 0.42 ± 0.03 Compared to the intact group + 295% + 14% Compared to the control group -71% Atherogenic coefficient 0.81 ± 0.03 4.91 ± 0.05 1.11 ± 0.01

Claims (1)

The method of non-drug reduction of hyperlipidemia in the experiment, characterized in that beet pectin in the amount of 100 μg / kg per day for 21 days is introduced into the diet of white outbred rats at the same time as the atherogenic diet.